Equities research analysts expect OpGen, Inc. (NASDAQ:OPGN) to report ($0.06) earnings per share for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for OpGen’s earnings. OpGen reported earnings per share of ($0.21) during the same quarter last year, which would indicate a positive year over year growth rate of 71.4%. The company is expected to issue its next earnings report on Thursday, March 22nd.

On average, analysts expect that OpGen will report full year earnings of ($0.41) per share for the current year. For the next financial year, analysts expect that the business will post earnings of ($0.15) per share. Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow OpGen.

Several analysts have issued reports on OPGN shares. Zacks Investment Research downgraded shares of OpGen from a “buy” rating to a “hold” rating in a report on Saturday, August 26th. HC Wainwright reaffirmed a “buy” rating and set a $1.00 price objective on shares of OpGen in a report on Tuesday, October 24th.

Shares of OpGen (NASDAQ OPGN) opened at $0.27 on Friday. The company has a quick ratio of 0.19, a current ratio of 0.29 and a debt-to-equity ratio of -0.55. OpGen has a 12-month low of $0.21 and a 12-month high of $3.10.

TRADEMARK VIOLATION WARNING: This report was first posted by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.dailypolitical.com/2017/11/11/opgen-inc-opgn-expected-to-post-earnings-of-0-06-per-share.html.

An institutional investor recently raised its position in OpGen stock. Vanguard Group Inc. boosted its position in shares of OpGen, Inc. (NASDAQ:OPGN) by 1.6% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 342,860 shares of the medical research company’s stock after purchasing an additional 5,500 shares during the period. Vanguard Group Inc. owned about 1.25% of OpGen worth $219,000 at the end of the most recent quarter. Institutional investors and hedge funds own 10.86% of the company’s stock.

OpGen Company Profile

OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.

Get a free copy of the Zacks research report on OpGen (OPGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OpGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.